MicroRNA expression profiles of esophageal cancer.

OBJECTIVE Expression of microRNAs by array analysis provides unique profiles for classifying tissues and tumors. The purpose of our study was to examine microRNA expression in Barrett esophagus and esophageal cancer to identify potential markers for disease progression. METHODS MicroRNA was isolated from 35 frozen specimens (10 adenocarcinoma, 10 squamous cell carcinoma, 9 normal epithelium, 5 Barrett esophagus, and 1 high-grade dysplasia). MicroRNA expression was analyzed with Ambion bioarrays (Ambion, Austin, Tex) containing 328 human microRNA probes. RESULTS Unsupervised hierarchic clustering resulted in four major branches corresponding with four histologic groups. One branch consisted of 7 normal epithelium samples and 1 squamous cell carcinoma sample. The second branch consisted of 7 squamous cell carcinoma samples and 1 normal epithelium sample. The third branch contained 4 Barrett esophagus samples and 1 squamous cell carcinoma sample. The fourth contained all the adenocarcinoma samples and 1 sample each of Barrett esophagus, normal epithelium, squamous cell carcinoma, and high-grade dysplasia. Supervised classification with principal component analysis determined that the normal epithelium samples were more similar to the squamous cell carcinoma tumors, whereas the Barrett esophagus samples were more similar to adenocarcinoma. Pairwise comparisons between sample types revealed microRNAs that may be markers of tumor progression. Both mir_203 and mir_205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. The mir_21 expression was 3- to 5-fold higher in both tumors than in normal epithelium. Prediction analysis of microarray classified 3 Barrett esophagus samples as Barrett esophagus, 1 as adenocarcinoma, and 1 as normal epithelium. CONCLUSION Expression profiles of miRNA distinguish esophageal tumor histology and can discriminate normal tissue from tumor. MicroRNA expression may prove useful for identifying patients with Barrett esophagus at high risk for progression to adenocarcinoma.

[1]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[2]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[3]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[4]  David F Ransohoff,et al.  Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. , 2002, JAMA.

[5]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Sugarbaker,et al.  Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. , 2001, The Annals of thoracic surgery.

[7]  J H Peters,et al.  Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. , 1999, Annals of surgery.

[8]  D. Ransohoff,et al.  Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. , 2002, JAMA.

[9]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Shibata,et al.  Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays , 2002, Oncogene.

[11]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[12]  Yan Xu,et al.  Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis , 2006, Oncogene.

[13]  A. Csendes,et al.  Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[14]  Govind Bhagat,et al.  EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. , 2005, Gastrointestinal endoscopy.

[15]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[16]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Welch,et al.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[18]  R. Heitmiller,et al.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. , 1996, Annals of surgery.

[19]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[20]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[21]  G. Portale,et al.  Predictive factors of coexisting cancer in Barrett’s high-grade dysplasia , 2006, Surgical Endoscopy And Other Interventional Techniques.

[22]  A. Cameron.  Epidemiology of Barrett's esophagus and adenocarcinoma. , 2002, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[23]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[24]  M. Krasna,et al.  Multimodality treatment of esophageal cancer. , 2005, The Surgical clinics of North America.

[25]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[26]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[27]  V. Moreno,et al.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.

[28]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[29]  J. Goldblum,et al.  Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. , 1999, Gastrointestinal endoscopy.

[30]  James S. McCaughan,et al.  Minimally Invasive Esophagectomy: Outcomes in 222 Patients , 2003, Annals of surgery.

[31]  N. Altorki,et al.  Epidemiology and molecular biology of Barrett's adenocarcinoma. , 1997, Seminars in surgical oncology.

[32]  T. Yeatman,et al.  Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma , 2005, Clinical Cancer Research.

[33]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[34]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[35]  Bergein F Overholt,et al.  Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. , 2007, Gastrointestinal endoscopy.

[36]  John T. Chang,et al.  Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. , 2004, Archives of internal medicine.

[37]  M. Michael,et al.  HP24
MICRORNA EXPRESSION PROFILES IN BARRETT’S OESOPHAGUS , 2007 .

[38]  N. Altorki,et al.  High Grade Dysplasia: Surveillance, Mucosal Ablation, or Resection? , 2003, World Journal of Surgery.